ARGX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $48.7B · 1,863 employees
189
SEC Filings
$852.5
Close 2026-06-24
1,863
Employees
Business Summary
argenx SE is a biopharmaceutical company focused on developing and commercializing antibody-based therapies for autoimmune diseases. Its commercial products include VYVGART (efgartigimod alfa) and VYVGART SC (subcutaneous formulation), approved for generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP, Japan only). The company leverages its antibody technology platforms and conducts clinical trials across multiple autoimmune indications globally.
Look up ARGX using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on ARGX, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/ARGX (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.